1221069-57-3

Upstream product

• 106-47-8 4-chloro-aniline 
• 115592-30-8 ethyl 1-(4-chlorophenyl)-5-cyano-4-methyl-6-oxo-1,6-dihydrodihydropyridazine-3-carboxylate 

Downstream Products

• 1221069-64-2 5-amino-3-(4-chlorophenyl)-N-ethyl-N-methyl-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxamide 
• 1221069-63-1 5-amino-3-(4-chlorophenyl)-N,N-dimethyl-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxamide 
• 1221069-60-8 5-amino-3-(4-chlorophenyl)-N-ethyl-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxamide 
• 1221069-61-9 5-amino-3-(4-chlorophenyl)-N-isopropyl-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxamide 
• 1221069-59-5 5-amino-3-(4-chlorophenyl)-N-methyl-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxamide 
• 1221069-62-0 5-amino-3-(4-chlorophenyl)-N-cyclopropyl-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxamide 
• 1391030-19-5 3-(4-chlorophenyl)-4,5-dioxo-3,4,5,7-tetrahydrothieno[3,4-d]pyridazine-1-carboxylic acid 
• 1391030-20-8 3-(4-chlorophenyl)-N-isopropyl-4,5-dioxo-3,4,5,7-tetrahydrothieno[3,4-d]pyridazine-1-carboxamide 

Relevant academic research and scientific papers

Aminothienopyridazine inhibitors of tau aggregation: Evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties

Previous studies demonstrated that members of the aminothienopyridazine (ATPZ) class of tau aggregation inhibitors exhibit a promising combination of in vitro activity as well as favorable pharmacokinetic properties (i.e., brain-penetration and oral bioavailability). Here we report the synthesis and evaluation of several new analogues. These studies indicate that the thienopyridazine core is essential for inhibition of tau fibrillization in vitro, while the choice of the appropriate scaffold decoration is critical to impart desirable ADME-PK properties. Among the active, brain-penetrant ATPZ inhibitors evaluated, 5-amino-N-cyclopropyl-3-(4-fluorophenyl)-4-oxo-3,4- dihydrothieno[3,4-d]pyridazine-1-carboxamide (43) was selected to undergo maximum tolerated dose and one-month tolerability testing in mice. The latter studies revealed that this compound is well-tolerated with no notable side-effects at an oral dose of 50 mg/kg/day.

AMINOTHIENOPYRIDAZINE INHIBITORS OF TAU ASSEMBLY

The present invention is directed to methods of inhibiting a tauopathy in a patient by administration of a compound of formula (I): Novel aminothienopyridazine compounds are also described.

Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of Tau aggregation

Agents capable of preventing the misfolding and sequestration of the microtubule-stabilizing protein tau into insoluble fibrillar aggregates hold considerable promise for the prevention and/or treatment of neurodegenerative tauopathies such as Alzheimer's